Bronchiectasis Drugs Market by Product, Distribution Channel, and Geography - Forecast and Analysis 2023-2027

Published: Jun 2023

Pages: 168

SKU: IRTNTR74635

Snapshot

Bronchiectasis Drugs Market Analysis Report 2023-2027:

The bronchiectasis drugs market size is estimated to grow at a CAGR of 9.98% between 2022 and 2027. The market size is forecast to increase by USD 326.01 million. The growth of the market depends on several factors, including the increasing cases of associated risk factors, the availability of low-cost off-label generics, and the surge in the geriatric population.

This bronchiectasis drugs market report extensively covers market segmentation by product (antibiotics, expectorants, and others), distribution channel (offline and online), and geography (North America, Europe, Asia, and Rest of the World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the size of the Bronchiectasis Drugs Market During the Forecast Period?

To learn more about this report, View Report Sample

Bronchiectasis Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

The Increasing cases of associated risk factors are notable driving the market growth, although factors such as the growing awareness about bronchiectasis ?may impede?the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Bronchiectasis Drugs Market Driver

The increasing cases of associated risks are the key factor driving the growth of the bronchiectasis drugs market. Bronchiectasis frequently happens due to health conditions such as humoral immunodeficiency, inflammatory bowel disease (Crohn's disease and ulcerative colitis), rheumatologic diseases (rheumatoid arthritis and Sjogren's disease), chronic obstructive pulmonary disease (COPD), cystic fibrosis. Across the globe, these diseases are of great concern. The increased prevalence of bronchiectasis globally is also a result of various external factors, including an increase in the number of patients with related diseases.

The external factors include exposure to poisonous gases owing to various occupations such as mining, working in chemical laboratories and manufacturing plants, increasing air pollution, and growing smoking habits. Therefore growing cases of risk factors and increased exposure to different forms of poisonous gases are increasing the probability of bronchiectasis infection. The need for treatment options is increasing as a result of the multitudinous etiology of bronchiectasis, it is expected to have a positive impact on the global bronchiectasis drugs market over the forecast period.

Significant Bronchiectasis Drugs Market Trends

The growing awareness about bronchiectasis is the primary trend in the bronchiectasis drug market. Bronchiectasis is often misunderstood as a common cough and cold, as the symptoms of most respiratory tract infections are overlapped. This results in underdiagnosing the infection, which reduces the use of treatment options and thus affects the growth of the market. In order to increase the prevalence of this disease, primary and secondary healthcare centers need to be better informed about it.

Many awareness programs have been put in place by a number of public and private organizations across the world to inform people about this. In addition, some companies are regularly organizing educational programs to inform healthcare professionals and patients of available therapeutic options for the treatment of bronchiectasis. Such awareness programs about the medications available for the treatment of bronchiectasis are expected to positively impact the market during the forecast period.

Major bronchiectasis drugs market Challenge

The lack of approved drugs for bronchiectasis is the major challenge to the growth of the global bronchiectasis drug market. The treatment options for bronchiectasis consist of medications, CPT, the use of lung airway devices, oxygen therapy, and surgery. The reason for the infection in bronchiectasis can be different, but a wide range of treatments is required in some cases. There are no authorized products in the global bronchiectasis drug market at present. However, drugs are used as OTC and off-label drug therapies largely to relieve the symptoms of other conditions, thus increasing the risk of bronchiectasis. However, human use of antibiotics leads to a process of drug resistance.

Moreover, patient adherence to treatment continues to decline as a result of resistance to antibiotics. The growth of the market is projected to be limited due to the lack of availability of approved medicinal products, along with a weak therapeutic effect of Symptomative Medicines. In addition, there are only a few drugs available for the treatment of bronchiectasis. Also, R & D is focused more on the development of substitute therapies. Thus, the lack of approved drug therapies is expected to hinder the growth of the market in focus during the forecast period

Bronchiectasis Drugs Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Bronchiectasis Drugs Market Customer Landscape

Who are the Major Bronchiectasis Drugs Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product launches, to enhance their presence in the market.

AbbVie Inc.: The company offers breast cancer therapeutics such as Veliparib, a PARP inhibitor.

The research report also includes detailed analyses of the competitive landscape of the market and information about 20 market vendors, including

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Bronchiectasis Drugs Market?

The market share growth by the antibiotics segment will be significant during the forecast period. This segment consists of a wide range of off-label drugs, such as azithromycin, erythromycin, doxycycline, amoxicillin, ciprofloxacin, and macrolides, which are used for the treatment of bronchiectasis. Due to the absence of approved drug therapy for bronchiectasis, these antibiotics are very common in use.

Get a glance at the market contribution of various segments View the PDF Sample

The antibiotics segment ?was valued at?USD 225.46 million?in 2017 and continue to grow by 2021. The treatment of bronchiectasis with antibiotics is broadly classified as exacerbation treatment, chronic suppressive treatment, and eradication treatment. Antibiotic resistance in patients poses a challenge to the growth of the segment. A single antibiotic may not be able to inhibit all pathogens present and near the respiratory tract, even if every pathogen associated with the respiratory system is resistant to various antibiotics. Therefore, in order to attain the aim of a clinically meaningful result, different antibiotics must be used with each other.

Which are the Key Regions for the Bronchiectasis Drugs Market?

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. In this region, the increasing sales of various off-label drug therapies approved for other chronic respiratory conditions and the increasing prevalence of chronic respiratory diseases have fueled the growth of the bronchiectasis drug market.

The COVID-19 pandemic had a negative impact on the growth of the regional bronchiectasis drugs market in 2020. However, in December 2020, the initiation of COVID-19 vaccination drives and the subsequent lifting of lockdown restrictions led to the gradual resumption of operations in pharmaceutical manufacturing and logistics units, which helped in easing R&D-related constraints. The regional bronchiectasis drugs market is expected to witness growth during the forecast period.

Segment Overview

The bronchiectasis drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.

Product Outlook (USD Million, 2017 - 2027)
- Antibiotics
- Expectorants
- Others
Distribution Channel Outlook (USD Million, 2017 - 2027)
- Online
- Offline
Region Outlook (USD Million, 2017 - 2027)
- North America
  - The U.S.
  - Canada
- Europe
  - U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- ROW
  - Australia
  - Argentina
  - Rest of World

Parent Market Analysis

Technavio categorizes the as a part of the global bronchiectasis drugs market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent, the global pharmaceuticals, market covers products and companies engaged in research and development (R&D) or production of generic drugs, non-generic drugs, and veterinary drugs. Our market research report has extensively covered external factors influencing the parent market growth during the forecast period.

Bronchiectasis Drugs Market Scope
Report Coverage	Details
Page number	168
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 9.98%
Market growth 2023-2027	USD 326.01 million
Market structure	Fragmented
YoY growth 2022-2023(%)	9.09
Regional analysis	North America, Europe, Asia, and Rest of the World (ROW)
Performing market contribution	North America at 44%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Akorn Operating Co LLC, Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Dr Reddys Laboratories Ltd., Endo International Plc, GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Lupin Ltd., Neopharma Corp., Pfizer Inc., Reckitt Benckiser Group Plc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Virtus Pharmaceuticals LLC, Wockhardt Ltd., and Zydus Lifesciences Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View PDF Sample

What are the Key Data Covered in this Bronchiectasis Drugs Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the market between 2023 and 2027
Precise estimation of the market in focus on the parent market
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
Through analysis of the market’s competitive landscape and detailed information about vendors
Comprehensive analysis of factors that will challenge the growth of market vendors

We can help! Our analysts can customize this market research report to meet your requirements.

Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2022

3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global bronchiectasis drugs market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on global bronchiectasis drugs market 2017 - 2021 ($ million)

4.2 Product Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ million)

4.3 Distribution Channel Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ million)

4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Product

6.1 Market segments
- Exhibit 30: Chart on Product - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Product - Market share 2022-2027 (%)

6.2 Comparison by Product
- Exhibit 32: Chart on Comparison by Product
- Exhibit 33: Data Table on Comparison by Product

6.3 Antibiotics - Market size and forecast 2022-2027
- Exhibit 34: Chart on Antibiotics - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Antibiotics - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Antibiotics - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Antibiotics - Year-over-year growth 2022-2027 (%)

6.4 Expectorants - Market size and forecast 2022-2027
- Exhibit 38: Chart on Expectorants - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Expectorants - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Expectorants - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Expectorants - Year-over-year growth 2022-2027 (%)

6.5 Others - Market size and forecast 2022-2027
- Exhibit 42: Chart on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 43: Data Table on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 44: Chart on Others - Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on Others - Year-over-year growth 2022-2027 (%)

6.6 Market opportunity by Product
- Exhibit 46: Market opportunity by Product ($ million)
- Exhibit 47: Data Table on Market opportunity by Product ($ million)

7 Market Segmentation by Distribution Channel

7.1 Market segments
- Exhibit 48: Chart on Distribution Channel - Market share 2022-2027 (%)
- Exhibit 49: Data Table on Distribution Channel - Market share 2022-2027 (%)

7.2 Comparison by Distribution Channel
- Exhibit 50: Chart on Comparison by Distribution Channel
- Exhibit 51: Data Table on Comparison by Distribution Channel

7.3 Offline - Market size and forecast 2022-2027
- Exhibit 52: Chart on Offline - Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Data Table on Offline - Market size and forecast 2022-2027 ($ million)
- Exhibit 54: Chart on Offline - Year-over-year growth 2022-2027 (%)
- Exhibit 55: Data Table on Offline - Year-over-year growth 2022-2027 (%)

7.4 Online - Market size and forecast 2022-2027
- Exhibit 56: Chart on Online - Market size and forecast 2022-2027 ($ million)
- Exhibit 57: Data Table on Online - Market size and forecast 2022-2027 ($ million)
- Exhibit 58: Chart on Online - Year-over-year growth 2022-2027 (%)
- Exhibit 59: Data Table on Online - Year-over-year growth 2022-2027 (%)

7.5 Market opportunity by Distribution Channel
- Exhibit 60: Market opportunity by Distribution Channel ($ million)
- Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 63: Chart on Market share by geography 2022-2027 (%)
- Exhibit 64: Data Table on Market share by geography 2022-2027 (%)

9.2 Geographic comparison
- Exhibit 65: Chart on Geographic comparison
- Exhibit 66: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2022-2027
- Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%)

9.4 Europe - Market size and forecast 2022-2027
- Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%)

9.5 Asia - Market size and forecast 2022-2027
- Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%)

9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

9.7 US - Market size and forecast 2022-2027
- Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%)

9.8 Germany - Market size and forecast 2022-2027
- Exhibit 87: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 88: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 89: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on Germany - Year-over-year growth 2022-2027 (%)

9.9 UK - Market size and forecast 2022-2027
- Exhibit 91: Chart on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 92: Data Table on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 93: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on UK - Year-over-year growth 2022-2027 (%)

9.10 China - Market size and forecast 2022-2027
- Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)

9.11 Canada - Market size and forecast 2022-2027
- Exhibit 99: Chart on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 100: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 101: Chart on Canada - Year-over-year growth 2022-2027 (%)
- Exhibit 102: Data Table on Canada - Year-over-year growth 2022-2027 (%)

9.12 Market opportunity by geography
- Exhibit 103: Market opportunity by geography ($ million)
- Exhibit 104: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 105: Impact of drivers and challenges in 2022 and 2027

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 106: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 107: Overview on factors of disruption

11.4 Industry risks
- Exhibit 108: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 109: Vendors covered

12.2 Market positioning of vendors
- Exhibit 110: Matrix on vendor position and classification

12.3 AbbVie Inc.
- Exhibit 111: AbbVie Inc. - Overview
- Exhibit 112: AbbVie Inc. - Product / Service
- Exhibit 113: AbbVie Inc. - Key news
- Exhibit 114: AbbVie Inc. - Key offerings

12.4 Akorn Operating Co LLC
- Exhibit 115: Akorn Operating Co LLC - Overview
- Exhibit 116: Akorn Operating Co LLC - Product / Service
- Exhibit 117: Akorn Operating Co LLC - Key offerings

12.5 Amneal Pharmaceuticals Inc.
- Exhibit 118: Amneal Pharmaceuticals Inc. - Overview
- Exhibit 119: Amneal Pharmaceuticals Inc. - Business segments
- Exhibit 120: Amneal Pharmaceuticals Inc. - Key news
- Exhibit 121: Amneal Pharmaceuticals Inc. - Key offerings
- Exhibit 122: Amneal Pharmaceuticals Inc. - Segment focus

12.6 Aurobindo Pharma Ltd.
- Exhibit 123: Aurobindo Pharma Ltd. - Overview
- Exhibit 124: Aurobindo Pharma Ltd. - Product / Service
- Exhibit 125: Aurobindo Pharma Ltd. - Key offerings

12.7 Bayer AG
- Exhibit 126: Bayer AG - Overview
- Exhibit 127: Bayer AG - Business segments
- Exhibit 128: Bayer AG - Key news
- Exhibit 129: Bayer AG - Key offerings
- Exhibit 130: Bayer AG - Segment focus

12.8 Boehringer Ingelheim International GmbH
- Exhibit 131: Boehringer Ingelheim International GmbH - Overview
- Exhibit 132: Boehringer Ingelheim International GmbH - Business segments
- Exhibit 133: Boehringer Ingelheim International GmbH - Key news
- Exhibit 134: Boehringer Ingelheim International GmbH - Key offerings
- Exhibit 135: Boehringer Ingelheim International GmbH - Segment focus

12.9 Dr Reddys Laboratories Ltd.
- Exhibit 136: Dr Reddys Laboratories Ltd. - Overview
- Exhibit 137: Dr Reddys Laboratories Ltd. - Business segments
- Exhibit 138: Dr Reddys Laboratories Ltd. - Key offerings
- Exhibit 139: Dr Reddys Laboratories Ltd. - Segment focus

12.10 Endo International Plc
- Exhibit 140: Endo International Plc - Overview
- Exhibit 141: Endo International Plc - Business segments
- Exhibit 142: Endo International Plc - Key news
- Exhibit 143: Endo International Plc - Key offerings
- Exhibit 144: Endo International Plc - Segment focus

12.11 GlaxoSmithKline Plc
- Exhibit 145: GlaxoSmithKline Plc - Overview
- Exhibit 146: GlaxoSmithKline Plc - Business segments
- Exhibit 147: GlaxoSmithKline Plc - Key news
- Exhibit 148: GlaxoSmithKline Plc - Key offerings
- Exhibit 149: GlaxoSmithKline Plc - Segment focus

12.12 Hikma Pharmaceuticals Plc
- Exhibit 150: Hikma Pharmaceuticals Plc - Overview
- Exhibit 151: Hikma Pharmaceuticals Plc - Business segments
- Exhibit 152: Hikma Pharmaceuticals Plc - Key offerings
- Exhibit 153: Hikma Pharmaceuticals Plc - Segment focus

12.13 Lupin Ltd.
- Exhibit 154: Lupin Ltd. - Overview
- Exhibit 155: Lupin Ltd. - Product / Service
- Exhibit 156: Lupin Ltd. - Key news
- Exhibit 157: Lupin Ltd. - Key offerings

12.14 Neopharma Corp.
- Exhibit 158: Neopharma Corp. - Overview
- Exhibit 159: Neopharma Corp. - Product / Service
- Exhibit 160: Neopharma Corp. - Key news
- Exhibit 161: Neopharma Corp. - Key offerings

12.15 Pfizer Inc.
- Exhibit 162: Pfizer Inc. - Overview
- Exhibit 163: Pfizer Inc. - Product / Service
- Exhibit 164: Pfizer Inc. - Key news
- Exhibit 165: Pfizer Inc. - Key offerings

12.16 Reckitt Benckiser Group Plc
- Exhibit 166: Reckitt Benckiser Group Plc - Overview
- Exhibit 167: Reckitt Benckiser Group Plc - Business segments
- Exhibit 168: Reckitt Benckiser Group Plc - Key offerings
- Exhibit 169: Reckitt Benckiser Group Plc - Segment focus

12.17 Viatris Inc.
- Exhibit 170: Viatris Inc. - Overview
- Exhibit 171: Viatris Inc. - Business segments
- Exhibit 172: Viatris Inc. - Key news
- Exhibit 173: Viatris Inc. - Key offerings
- Exhibit 174: Viatris Inc. - Segment focus

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 175: Inclusions checklist
- Exhibit 176: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 177: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 178: Research methodology
- Exhibit 179: Validation techniques employed for market sizing
- Exhibit 180: Information sources

13.5 List of abbreviations
- Exhibit 181: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

bronchiectasis drugs market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis